Trailing Twelve Months Revenue Growth: Olema Pharmaceuticals (OLMA)

Graphic logo of Olema Corp (OLMA)

Flawless temperature-controlled transport of biomaterials ensures the success of Olema Pharmaceuticals trials. The LTM annual sales growth rate demonstrates volatility in commercial metrics, where the current value is 0.00. AI-driven bioscreening automation optimizes laboratory processes, while the race to accelerate the time-to-market for oncology drugs defines the company's current competitive strategy.

OLMA (Olema Pharmaceuticals) Sales Growth YoY (TTM) history from 02/11/2024 to 11/18/2026

olema.com (OLMA) - metric breakdowns and financial figures

- company stock exchange capitalization indicators:
Fundamental company valuation:Olema Corp
Mass-produced product of Olema Pharmaceuticals

For the biotechnology company Olema Pharmaceuticals (OLMA), which is scaling Phase 3 trials of palazestrant, revenue often exhibits a specific nature, making income monitoring critical. This indicator captures the daily change in the growth rate of total revenue over the last 12 months, allowing investors to assess the speed of business expansion and operational resilience through the dynamics of year-over-year (TTM) commercial revenue growth.